Fiduciary Alliance’s Cardlytics CDLX Stock Holding History

Fiduciary Alliance’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-220	Closed	-$13.9K	–	280
2023 Q2	$13.9K	Buy	+220	New	+$13.3K	﹤0.01%	499

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fiduciary Alliance's CDLX Position: Q3 2023 in Review

Fiduciary Alliance sold out of Cardlytics (CDLX) in Q3 2023, closing a stake of 220 shares — an estimated $13.9K sold.

Fiduciary Alliance first reported a position in CDLX in Q2 2023 and held it in 1 quarter. The position peaked at $13.9K in Q2 2023. 112 funds tracked by Wall St. Rank hold CDLX as of Q3 2023.

Fiduciary Alliance reported no remaining Cardlytics position as of Q3 2023 after selling out during the quarter.
Fiduciary Alliance sold 220 Cardlytics shares in Q3 2023, an estimated $13.9K.
Fiduciary Alliance first reported a position in Cardlytics in Q2 2023 and held it in 1 quarter.
Fiduciary Alliance's Cardlytics position peaked at $13.9K in Q2 2023.
112 funds tracked by Wall St. Rank held Cardlytics as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.